HRES 1285 · 119th Congress
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Latest action
Referred to the House Committee on Energy and Commerce.
Sponsor
Diana DeGetteDemocrat · CO-1Profile →Cosponsors (12)
12 D
- Becca BalintVTMay 14, 2026
- Wesley BellMO-1May 14, 2026
- Katherine M. ClarkMA-5May 14, 2026
- Maxine DexterOR-3May 14, 2026
- Jesús G. "Chuy" GarcíaIL-4May 14, 2026
- Jennifer L. McClellanVA-4May 14, 2026
- Seth MoultonMA-6May 14, 2026
- Eleanor Holmes NortonDCMay 14, 2026
- Brittany PettersenCO-7May 14, 2026
- Ayanna PressleyMA-7May 14, 2026
- Paul TonkoNY-20May 14, 2026
- Nydia M. VelázquezNY-7May 14, 2026